ArticleMolecular cancer research : MCR2021
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.Leukemia · 2026Article
- Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death.EJHaem · 2025Article
- Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.Blood cancer journal · 2025Article
- Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement.Frontiers in oncology · 2025Article
- Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma.Cell & bioscience · 2024Review
- Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population.Haematologica · 2024Article
- Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma.Cancers · 2024Article
- Transformation of marginal zone lymphoma into high-grade B-cell lymphoma expressing terminal deoxynucleotidyl transferase: A case report.World journal of clinical cases · 2024Article
- MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation andHaematologica · 2024Article
- High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.Blood advances · 2023Article
- The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.Scientific reports · 2023Article
- Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma.Blood cancer journal · 2023Article
- Maintenance regimen of GM-CSF with rituximab and lenalidomide improves survival in high-risk B-cell lymphoma by modulating natural killer cells.Cancer medicine · 2023Article
- Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.Cancer medicine · 2023Article
- Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.Haematologica · 2023Article
- Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters.Journal of clinical and experimental hematopathology : JCEH · 2023Article
- An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.EJHaem · 2022Article
- PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma.Current medical science · 2022Article
- Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma.American journal of cancer research · 2022Article
- Double-hit lymphoma: optimizing therapy.Hematology. American Society of Hematology. Education Program · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 20 institutions in 8 countries.
Manman Deng *Duke University Medical Center, Division of Hematopathology and Department of Pathology, Durham, North Carolina.
Zijun Y Xu-Monette *Duke University Medical Center, Division of Hematopathology and Department of Pathology, Durham, North Carolina.
Lan V Pham *Phamacyclics, an Abbvie Company, San Francisco, California.
Xudong Wang *Duke University Medical Center, Division of Hematopathology and Department of Pathology, Durham, North Carolina.
Alexandar TzankovInstitute of Pathology, University Hospital Basel, Switzerland.ORCID https://orcid.org/0000-0002-1100-3819
Xiaosheng FangDuke University Medical Center, Division of Hematopathology and Department of Pathology, Durham, North Carolina.
Feng ZhuDuke University Medical Center, Division of Hematopathology and Department of Pathology, Durham, North Carolina.
Carlo ViscoDepartment of Medicine and Division of Hematology, University of Verona, Verona, Italy.ORCID https://orcid.org/0000-0003-2863-0883
Govind BhagatColumbia University Medical Center and New York Presbyterian Hospital, New York, New York.
Karen DybkaerAalborg University Hospital, Aalborg, Denmark.ORCID https://orcid.org/0000-0003-2488-435X
April ChiuMayo Clinic, Rochester, Minnesota.
Wayne TamWeill Medical College of Cornell University, New York, New York.
Youli ZuThe Methodist Hospital, Houston, Texas.
Eric D HsiCleveland Clinic, Cleveland, Ohio.
Hua YouAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Jooryung HuhAsan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
Maurilio PonzoniSan Raffaele H. Scientific Institute, Milan, Italy.ORCID https://orcid.org/0000-0002-0055-325X
Andrés J M FerreriSan Raffaele H. Scientific Institute, Milan, Italy.
Michael B MøllerOdense University Hospital, Odense, Denmark.ORCID https://orcid.org/0000-0003-2041-3630
Benjamin M ParsonsGundersen Lutheran Health System, La Crosse, Wisconsin.ORCID https://orcid.org/0000-0002-5634-2937
Fredrick HagemeisterDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Han van KriekenRadboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-8105-0450
Miguel A PirisHospital Universitario Marqués de Valdecilla, Santander, Spain.
Jane N WinterFeinberg School of Medicine, Northwestern University, Chicago, Illinois.ORCID https://orcid.org/0000-0001-7542-3305
Yong LiDepartment of Medicine, Baylor College of Medicine, Houston, Texas.
Bing XuDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, Fujian, China. ken.young@duke.edu xubingzhangjian@126.com PLiu@incyte.com.
Phillip LiuApplied Technology Group, Incyte Research Institute, Wilmington, Delaware. ken.young@duke.edu xubingzhangjian@126.com PLiu@incyte.com.
Ken H YoungDuke University Medical Center, Division of Hematopathology and Department of Pathology, Durham, North Carolina. ken.young@duke.edu xubingzhangjian@126.com PLiu@incyte.com.
Duke University · USSan Raffaele University of Rome · ITAalborg University Hospital · DKBaylor College of Medicine · USCleveland Clinic · USCommunity Health Systems - Lutheran Hospital · USCornell University · USFirst Affiliated Hospital of Xiamen University · CNGuangzhou Medical University Cancer Hospital · CNIncyte (United States) · USMarqués de Valdecilla University Hospital · ESMayo Clinic · USMethodist Hospital · USNewYork–Presbyterian Hospital · USNorthwestern University · USOdense University Hospital · DKPharmacyclics (United States) · USRadboud University Nijmegen · NLThe University of Texas MD Anderson Cancer Center · USUniversity Hospital of Basel · CH
Funding
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental CoR01CA138688 · NCI · UNIVERSITY OF LOUISVILLE · PI LI, YONG · 2009 to 2017
$2.9MMYC as a Biomarker in Aggressive Non-Hodgkin LymphomaR01CA187415 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, YONG · 2015 to 2019
$2.2MGenetic and Epigenetic Biomarkers for B-cell LymphomaR01CA233490 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YOUNG, KEN H. · 2019 to 2023
$1.8MDeep Sequencing of Small Regulatory RNAs in Diffuse Large B cell LymphomaRC1CA146299 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI XIAO, CHANGCHUN · 2009 to 2010
$1000kNCI NIH HHS R01 CA138688NCI NIH HHS R01 CA187415NCI NIH HHS R01 CA233490NCI NIH HHS RC1 CA146299
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the major type of aggressive B-cell lymphoma. High-grade B-cell lymphoma (HGBCL) with
Indexed as
ApoptosisCell Line, TumorGene Expression ProfilingHumansLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-mycTumor Suppressor Protein p53Proto-Oncogene Proteins c-mycTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.